p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation

Oral Oncology

Volumn 34, Issue 6, 1998, Pages 529-537

  Yoneda, K ^a   Yamamoto, T ^a   Osaki, T ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

5 Fluorouracil; Apoptosis; p21; p53; Radiation; Squamous cell carcinoma cells

Indexed keywords

FLUOROURACIL; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; GAMMA RADIATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FLUOROURACIL; GAMMA RAYS; GENES, P53; HUMANS; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0031787083     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(98)00036-0     Document Type: Article

References (49)

1. Huang M. E., Ye Y. C., Chen S. R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:1988;567-572.
2. Castaigne S., Chomienne C., Daniel M. T., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood. 76:1990;1704-1709.
3. Sharma R., Adam E., Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. British Journal of Cancer. 76:1997;1011-1016.
4. Cotter T. G., Glynn J. M., Echeverri F., Green D. R. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Research. 12:1992;773-780.
5. Ehinger M., Bergh G., Johnsson E., Gullberg U., Olsson I. The tumor suppressor gene p53 can mediate transforming the growth factor beta 1-induced differentiation of leukemic cells independently of activation of the retinoblastoma protein. Cell Growth and Differentiation. 8:1997;1127-1137.
6. Frost P., Ng C. P., Belldegrun A., Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cellular Immunology. 180:1997;70-83.
7. Sato M., Yoshida H., Kaji R., et al. Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy. Journal of Biological Response Modifier. 9:1990;329-334.
8. Ueta E., Osak T., Yamamoto T., Yoneda K. Induction of differentiation in maxillary adenoid cystic carcinomas by adoptive immunotherapy in combination with chemoradiotherapy. Oral Oncology, 1998;34:105-11.
9. Gottlieb T. M., Oren M. p53 in growth control and neoplasia. Biochimica et Biophysica Acta. 1287:1996;77-102.
10. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
11. El-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genetics. 1:1992;45-49.
12. El-Deiry W. S., Tokino T., Velculescu V. E., et al. WAF1, a potential mediator of p53 tumor suppression. Cell, 75:1993;817-825.
13. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
14. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
15. Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
16. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programed cell death. Cell. 74:1993;609-619.
17. Shivakumar C. V., Brown D. R., Deb S., Deb S. P. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Molecular and Cellular Biolology. 15:1995;6785-6793.
18. Lin D., Shields M. T., Ullrich S. J., Appella E., Mercer W. E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proceedings of the National Academy of Sciences of the U.S.A. 89:1992;9210-9214.
19. Miyashita T., Harigai M., Hanada M., Reed J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Research. 54:1994;3131-3135.
20. Lowe S. W., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
21. Cotter T. G., Glynn J. M., Echeverri F., Green D. R. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Research. 12:1992;773-780.
22. 2 to M transition: implications for gene therapy. Cancer Research. 57:1997;818-823.
23. Osaki T., Tatemoto Y., Yoneda K., Yamamoto T. Tumorigenicity of cell lines established from oral squamous cell carcinoma and its metastatic lymph nodes. Oral Oncology, European Journal of Cancer. 30B:1994;296-301.
24. Sherr C. J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
25. Sherr C. J., Roberts M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development. 9:1995;1149-1163.
26. Reynisdottir I., Massague J. The subcellular locations of p15 (Ink 4b) and p27 (Kip 1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes and Development. 11:1997;492-503.
27. Weinstat-Saslow D., Merino M. J., Manrow R. E., et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Medicine. 1:1995;1257-1260.
28. Jiang W., Kahn S. M., Tomita N., Zhang Y. J., Lu S. H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Research. 52:1992;2980-2983.
29. Lane D. P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
30. Scheffner M., Huibregtse J. M., Vierstra R. D., Howley P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
31. Shkedy D., Gonen H., Bercovich B., Ciechanover A. Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. FEBS Letters. 348:1994;126-130.
32. Chen C. Y., Oliner J. D., Zhan Q., Fornace A. J. Jr., Vogelstein B., Kastan M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proceedings of the National Academy of Sciences of the U.S.A. 91:1994;2684-2688.
33. Chen J., Wu X., Lin J., Levine A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Molecular and Cellular Biology. 16:1996;2445-2452.
34. Ross J. mRNA stability in mammalian cells. Microbiological Reviews. 59:1995;423-450.
35. WAF/CIP1 expression in human breast carcinoma cells. Cancer Research. 56:1996;5055-5062.
36. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
37. Ikeda M., Jakoi L., Nevins J. R. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proceedings of the National Academy of Sciences of the U.S.A. 93:1996;3215-3220.
38. Geng Y., Eaton E. N., Picon M., et al. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene. 12:1996;1173-1180.
39. Zhang H., Hannon G. J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes and Development. 8:1994;1750-1758.
40. 2/M-phase transition. Molecular and Cellular Biology. 18:1998;546-557.
41. Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Molecular and Cellular Biology. 18:1998;629-643.
42. Reed J. C. Bcl-2 and the regulation of programmed cell death. Journal of Cell Biology. 124:1994;1-6.
43. Sato T., Hanada M., Bodrug S., et al. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proceedings of the National Academy of Sciences of the U.S.A. 91:1994;9238-9242.
44. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
45. Alnemri E. S., Livingston D. J., Nicholson D. W., et al. Human ICE/CED-3 protease nomenclature. Cell. 87:1996;171.
46. Nicholson D. W., Ali A., Thornberry N. A., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
47. Takahashi A., Alnemri E. S., Lazebnik Y. A., et al. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proceedings of the National Academy of Sciences of the U.S.A. 93:1996;8395-8400.
48. Kothakota S., Azuma T., Reinhard C., et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 278:1997;294-298.
49. Bossy-Wetzel E., Newmeyer D. D., Green D. R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. The EMBO Journal. 17:1998;37-49.